Abstract
Fluorine-18 labeled 2-fluoro-8-hydroxyquinoline ([(18)F]CABS13) is a promising positron emission tomography (PET) radiopharmaceutical based on a metal chelator developed to probe the "metal hypothesis of Alzheimer's disease". Herein, a practical radiosynthesis of [(18)F]CABS13 was achieved by radiofluorination followed by deprotection of an O-benzyloxymethyl group. Automated production and formulation of [(18)F]CABS13 resulted in 19 ± 5% uncorrected radiochemical yield, relative to starting [(18)F]fluoride, with ≥95% chemical and radiochemical purities, and high specific activity (>2.5 Ci/μmol) within 80 min. Temporal PET neuroimaging studies were carried out in female transgenic B6C3-Tg(APPswe,PSEN 1dE9)85Dbo/J (APP/PS1) and age-matched wild-type (WT) B6C3F1/J control mice at 3, 7, and 10 months of age. [(18)F]CABS13 showed an overall higher uptake and retention of radioactivity in the central nervous system of APP/PS1 mice versus WT mice with increasing age. However, PET/magnetic resonance imaging in normal nonhuman primates revealed that the tracer had low uptake in the brain and rapid formation of a hydrophilic radiometabolite. Identification of more metabolically stable (18)F-hydroxyquinolines that can be readily accessed ...Continue Reading
References
Jul 17, 1998·Journal of the Neurological Sciences·M A LovellW R Markesbery
Mar 11, 2000·Brain Research·S W SuhC J Frederickson
Jun 30, 2001·Neuron·R A ChernyA I Bush
Oct 7, 2004·Neurobiology of Aging·Joo-Yong LeeJae-Young Koh
May 14, 2005·Nature Reviews. Neuroscience·Christopher J FredericksonAshley I Bush
Jan 31, 2006·Aging Cell·Carlos OpazoAshley I Bush
Jul 11, 2008·Neuron·Paul A AdlardAshley I Bush
Jul 16, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Ashley I Bush, Rudolph E Tanzi
Aug 2, 2008·Lancet Neurology·Lars LannfeltUNKNOWN PBT2-201-EURO study group
Oct 28, 2008·Journal of Alzheimer's Disease : JAD·Ashley I Bush
Feb 19, 2010·Journal of Alzheimer's Disease : JAD·Noel G FauxAshley I Bush
Jun 18, 2010·Chemical Communications : Chem Comm·Sinchun LimPaul S Donnelly
Jan 5, 2011·CNS Neuroscience & Therapeutics·Silvio R Bareggi, Umberto Cornelli
Jul 4, 2012·Accounts of Chemical Research·Peter J Crouch, Kevin J Barnham
Mar 13, 2013·Lancet Neurology·Victor L VillemagneUNKNOWN Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group
Mar 20, 2013·ACS Chemical Biology·Masha G SavelieffMi Hee Lim
May 8, 2013·Journal of Alzheimer's Disease : JAD·Vladimir KepeJorge R Barrio
Aug 21, 2013·Chemical Communications : Chem Comm·Steven H LiangNeil Vasdev
Sep 28, 2013·Journal of the American Chemical Society·James L HickeyPaul S Donnelly
Dec 12, 2013·Journal of Labelled Compounds & Radiopharmaceuticals·Jason P HollandNeil Vasdev
Mar 29, 2014·Chemical Society Reviews·Lin ZhuHank F Kung
Jul 10, 2014·Nature Communications·Benjamin H RotsteinSteven H Liang
Dec 3, 2014·Biological Psychiatry·Jonathan McConathy, Yvette I Sheline
Feb 24, 2015·ACS Medicinal Chemistry Letters·Brian P CaryPeter J H Scott
Citations
Jan 16, 2016·ACS Chemical Neuroscience·Brian P CaryPeter J H Scott
Jan 12, 2016·Chemical Reviews·Sean PreshlockVéronique Gouverneur
Sep 24, 2015·ACS Medicinal Chemistry Letters·Steven H LiangNeil Vasdev
Nov 2, 2014·Stem Cell Reports·Richard L CarterAnthony W S Chan
Dec 13, 2016·Molecular Imaging·Timothy R DeGradoVal J Lowe
Feb 20, 2019·Chemical Communications : Chem Comm·So Jeong LeePeter J H Scott
Jan 9, 2020·Analytica Chimica Acta·Hui-Juan YuChongzhao Ran
Apr 24, 2021·Nuclear Medicine and Biology·Mitchell A KlennerTamim A Darwish
Jan 5, 2018·Molecular Pharmaceutics·Hema S KrishnanNeil Vasdev
Jul 26, 2019·ACS Chemical Neuroscience·Runrun WangRenhua Wu